Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 1 Issue 2, February 2020

Volume 1 Issue 2

Defining the phenogenomic landscape of breast cancer

Bodenmiller and colleagues pair imaging mass cytometry with multiplatform genomics to define single-cell phenotypic and genomic features of breast cancer with spatial context, finding associations with breast cancer subtypes and prognosis.

See Ali et al. and Angelo

Image: H R Ali, CRUK Cambridge Institute, University of Cambridge. Cover Design: Allen Beattie.

Editorial

  • Editorial |

    The convergence of big data and artificial intelligence is poised to revolutionize cancer research and care, from basic conceptual developments to translational and clinical applications. To reap these benefits, it is important to separate the hope from the hype.

Comment & Opinion

  • Comment |

    By integrating discovery science with clinical practice and therapeutic intervention, clinician-scientists fulfil a unique role in cancer research. However, their numbers are in decline, which is creating the need for flexible training and research opportunities to ensure their future.

    • Karen Noble
    • Joanna Owens
    • Charles Swanton
  • Comment |

    Low- and middle-income countries share the greatest burden of cancer mortality globally but lag behind high-income countries in terms of clinical trials. Here we discuss the challenges facing low- and middle-income countries and the opportunities for conducting trials of affordable, accessible and effective interventions relevant to the local population.

    • Bishal Gyawali
    • Gauthier Bouche
    • Nicolas André
  • Q&A |

    Zena Werb is Professor and Vice Chair of the Department of Anatomy at the University of California at San Francisco and Associate Director for Basic Science of the UCSF Helen Diller Family Comprehensive Cancer Center. Nature Cancer caught up with her at the 6th International Conference on Tumor Microenvironment and Cellular Stress organized by Aegean Conferences and held in Greece in the fall of 2019, to talk about her career and work in the tumor microenvironment field.

    • Alexia-Ileana Zaromytidou
  • Viewpoint |

    Filtered through the analytical power of artificial intelligence, the wealth of available biomedical data promises to revolutionize cancer research, diagnosis and care. In this Viewpoint, six experts discuss some of the challenges, exciting developments and future questions arising at the interface of machine learning and oncology.

    • Olga Troyanskaya
    • Zlatko Trajanoski
    • Nuria Oliver

News & Views

  • News & Views |

    Drug repurposing is an attractive strategy for extending the arsenal of oncology therapies. Screening of a large collection of existing non-oncology compounds against a panel of cancer cell lines now identifies several drugs capable of selectively inhibiting the growth of cancer cells.

    • Roderick L. Beijersbergen
  • News & Views |

    Tumor heterogeneity remains an obstacle to effective clinical management of breast cancer. Two new studies use high-dimensional imaging of single-cell protein expression in situ in clinical samples to link genomic alterations to multi-cellular features of the tumor microenvironment and reveal breast-cancer phenotypes associated with clinical outcome.

    • Leeat Keren
    • Michael Angelo
  • News & Views |

    Discerning and analyzing the mutational patterns that arise in the cancer genome can provide essential information on the process of tumorigenesis. An analytical framework and web-based tool now aim to aid in mutational signature assignment for improved tumor stratification.

    • Giovanni Ciriello
  • News & Views |

    Identifying indicators of response to immunotherapy is key for treatment decisions. Two studies now report that early changes in T cell repertoires and CD8+ memory effector cytotoxic T cells in peripheral blood correlate with response to immune-checkpoint inhibitors in metastatic melanoma and may serve as actionable biomarkers of immune activation.

    • Genevieve M. Boland
    • Keith T. Flaherty

Research

Amendments & Corrections

Search

Quick links